CRF Health Improves Patient and Site eCOA Experience
CRF Health, the leading electronic Clinical Outcome Assessment (eCOA) solutions provider announced several innovative enhancements to their TrialMax eCOA solutions.
CRF Health, the leading electronic Clinical Outcome Assessment (eCOA) solutions provider announced several innovative enhancements to their TrialMax eCOA solutions.
CRF Health has added new usability and patient retention enhancements that improve the efficiency of collecting clinical outcome data directly from patients and sites.
Among the improved features:
- Patient and site user experience improvements through meticulous user interface design and extensive usability testing, further reducing patient and site burden
- Investigators have on-demand access to study specific training directly on the TrialMax Slate, improving site compliance by ensuring training is available when needed as a reference or for new staff supporting the trial
- Ability to send SMS and email reminders to patients across all TrialMax eCOA solutions to keep patients engaged
- The new TrialMax Slate study dashboard clearly displays the questionnaire status of all patient visits. This enhancement reduces site burden and increases the efficiency of the eCOA collection process by highlighting required and incomplete questionnaires
For more information on the enhancements to TrialMax eCOA solutions or on how CRF Health supports clinical trials by fitting into patients’ lives, visit their website (
www.crfhealth.com
).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
